TR199802238T2 - Treatment of asthma with TNFR-Ig. - Google Patents

Treatment of asthma with TNFR-Ig.

Info

Publication number
TR199802238T2
TR199802238T2 TR1998/02238T TR9802238T TR199802238T2 TR 199802238 T2 TR199802238 T2 TR 199802238T2 TR 1998/02238 T TR1998/02238 T TR 1998/02238T TR 9802238 T TR9802238 T TR 9802238T TR 199802238 T2 TR199802238 T2 TR 199802238T2
Authority
TR
Turkey
Prior art keywords
asthma
treatment
tnfalfa
symmetrical
binding protein
Prior art date
Application number
TR1998/02238T
Other languages
Turkish (tr)
Inventor
Martin Renzetti Louis
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR199802238T2 publication Critical patent/TR199802238T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu bulus p55 TNF reseptörünün eriyebilen kismini ve bir hümen IgG1 veya IgG3'ün agir zincirli sabit bölgesinin birinci alani hariç tutulmak üzere tüm alanlarini ihtiva eden simerik bir TNFalfa baglayici proteinin etkili bir miktarini ihtiva eden bir kompozisyon ile astim ile savasa yönelik bir metoda ve astimin tedavisine matuf bir ilacin hazirlanmasi için bu gibi simerik bir TNFalfa baglayici proteinin kullanimina yönelmistir.This invention is a method for the treatment of asthma and asthma, with a composition containing an effective amount of a symmetrical TNFalfa binding protein containing the soluble portion of the p55 TNF receptor and all areas of a humen IgG1 or IgG3 excluding the first domain of the heavy chain constant region. It directed towards the use of such a symmetrical TNFalfa binding protein for the preparation of a targeted drug.

TR1998/02238T 1996-05-08 1997-05-02 Treatment of asthma with TNFR-Ig. TR199802238T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
TR199802238T2 true TR199802238T2 (en) 1999-02-22

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02238T TR199802238T2 (en) 1996-05-08 1997-05-02 Treatment of asthma with TNFR-Ig.

Country Status (15)

Country Link
EP (1) EP0910413A2 (en)
JP (1) JP2000510113A (en)
KR (1) KR20000010825A (en)
CN (1) CN1233189A (en)
AR (1) AR007020A1 (en)
AU (1) AU725408B2 (en)
BR (1) BR9708928A (en)
CA (1) CA2253557A1 (en)
CO (1) CO4820397A1 (en)
HR (1) HRP970224A2 (en)
MA (1) MA24169A1 (en)
PE (1) PE70698A1 (en)
TR (1) TR199802238T2 (en)
WO (1) WO1997041895A2 (en)
ZA (1) ZA973843B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044267A2 (en) * 1997-12-29 2000-10-18 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE602004013557D1 (en) * 2003-02-28 2008-06-19 Ares Trading Sa LIQUID FORMULATIONS OF THE TUMORNEKROSE FRACTURE BINDING PROTEIN TBP-1
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (en) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (en) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-binding proteins
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
CZ283219B6 (en) * 1994-07-22 1998-02-18 F. Hoffmann-La Roche Ag Use of chimeric protein binding tnf in the preparation of a pharmaceutical preparation for treating auto-immune diseases
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
AR007020A1 (en) 1999-10-13
PE70698A1 (en) 1998-11-18
BR9708928A (en) 2000-05-09
WO1997041895A2 (en) 1997-11-13
MA24169A1 (en) 1997-12-31
KR20000010825A (en) 2000-02-25
HRP970224A2 (en) 1998-04-30
CA2253557A1 (en) 1997-11-13
WO1997041895A3 (en) 1998-03-12
CN1233189A (en) 1999-10-27
ZA973843B (en) 1997-11-10
JP2000510113A (en) 2000-08-08
EP0910413A2 (en) 1999-04-28
AU2776497A (en) 1997-11-26
AU725408B2 (en) 2000-10-12
CO4820397A1 (en) 1999-07-28

Similar Documents

Publication Publication Date Title
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
ES2293973T3 (en) ANTIBODIES ANTI-CCR2 HUMANIZED AND METHODS OF USE OF THE SAME.
ATE168013T1 (en) HUMANIZED CHIMERA ANTI-''ICAM-1'' ANTIBODIES, PRODUCTION METHOD AND USE
EP1958965A3 (en) Agonist antibodies to a musk receptor, and their therapeutic uses
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
TR199800091T1 (en) Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies used as therapeutic agents for the treatment of immune diseases �.
ATE446973T1 (en) ANTI-CCR2 ANTIBODIES AND THEIR USE
HK1015413A1 (en) Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharaceutical compositions
DE69622074D1 (en) Cystine-silicone copolymers and their use for the treatment of keratinous materials
DE69737592D1 (en) MEDIUM AGAINST JUCKREIZ
PT800519E (en) STEROID RECEPTOR MODULATORS AND METHODS
EP1106183A3 (en) Antibodies to erbB2 and their therapeutic uses
DE69637781D1 (en) FOR THE IL-13 RECEPTOR SPECIFIC CHIMERIC PROTEINS AND ITS USES
BR9106392A (en) ANTI-ICAM-1 ANTIBODIES GRAFTED-HUMANIZED CDR, METHODS OF PREPARATION AND USE OF THE SAME
NZ329807A (en) NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
TR199802238T2 (en) Treatment of asthma with TNFR-Ig.
HK1025500A1 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
TR200001288T2 (en) 2-arylbenzo (b) thiophene useful in the treatment of estrogen withdrawal syndrome.
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
PT939809E (en) TIE-2 RECEIVER LIGANDS (TIE LINK 3 AND TIE LINK 4) AND YOUR USES
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
EP1028754A4 (en) Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
ES2130703T3 (en) CONJUGATES OF BENZODIAZEPINES AND PROTEINS AND THEIR USE FOR THE IMMUNOLOGICAL DETERMINATION OF BENZODIAZEPINES.
DE60020970D1 (en) MONOCLONAL ANTIBODY WITH SELECTIVE BINDING TO VGF AND USE FOR THE TREATMENT OF VGF DISEASES
MA26527A1 (en) OLIGO-THIOPHENES SERVING AS ANTIMETASTATIC AGENTS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.